PRINCETON, N.J., April 13, 2016 /PRNewswire/ -- Princeton based Biotech Support Group announced today that it has submitted provisional patents disclosing its data on many common proteins dysregulated in cancer. This breakthrough research shows that most of these biomarkers are believed to be dysregulated regardless of the primary tumor, stage of progression or tumor burden. The study, which collaborated with the Rutgers Center for Integrative Proteomics, shows the most distinguishable pattern of early dysregulation observable as a cancer serum phenotype to date. This forms the basis of a new commercialization plan featuring:
- Variant sub-populations (also known as proteoforms) of a common blood protein – Alpha-1-Antitrypsion, with functional reporting features severely distinguishable between cancer patients and normal/healthy individuals
- A measurable serum cancer profile that can be modeled with categorical biomarker proteins taken from inflammation, blood coagulation, tissue remodeling, and glycolysis, as well as new markers of unknown function.
The company will present its latest data as a poster report (LB-065) and announce its new commercialization plans at its Exhibit Booth # 658, at the upcoming AACR Annual Meeting 2016, April 16 - 20, 2016 in New Orleans, LA. The AACR meeting is expected to have well over 20,000 research scientists and physicians attending from all over the world.
"After several years of optimizing our methods, I am very pleased that we can now report what we believe are significant discoveries for improving outcomes of cancer patients. Within the framework of our intellectual property, we suggest it feasible to baseline monitor normal/healthy individuals and determine a dysregulation pattern associated with cancer generally but not necessarily for a particular primary tumor. Under the guidance of a physician, such dysregulated patterns may serve as a 'liquid biopsy,' forming an early indicator for cancer before clinical evidence. These same patterns may be prognostic and even offer therapy guidance. More refined algorithms for each of these purposes: early detection, prognosis and therapeutic options, can be made with a more detailed investigation in the future. We are looking forward to partnering with organizations to continue to move these new findings forward," commented Dr. Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
About Biotech Support Group LLC
Converging with cultural and technological disruptions forthcoming in heathcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to www.biotechsupportgroup.com.
Matthew Kuruc, 732-274-2866
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cancers-hidden-protein--protein-variants-could-be-the-key-to-early-cancer-diagnosis-300250717.html
SOURCE Biotech Support Group